Authors
Loading...
Retrospective cohort study finds adding venetoclax to hypomethylating agents increases response rates without improving survival in advanced myeloproliferative neoplasms, highlighting clinical...
Ciervo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: